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Ganciclovir for Invasive Cytomegalovirus Infection in Renal 
Allograft Recipients 
R. Hrebinko, M.L. Jordan, J.S. Dummer, D.P. Hickey, R. Shapiro, C. Vivas, T.E. Starzl, R.L. Simmons, 
and T.R. Hakala 
CYTOMEGALOVIRUS (CMV) is a major infectious 
complication of renal transplantation associated with 
significant morbidity and mortality. 1-3 Ganciclovir inhibits 
herpesvirus DNA polymerase4 and has shown antiviraJ 
effects in vivo in several reported clinical studies. 5-8 We 
report our experience with the use of ganciclovir in treat-
ing tissue-invasive CMV infection following cadaver renal 
transplantation. The results suggest that ganciclovir is well 
tolerated and effective in arresting the progress of invasive 
CMV to life-threatening disease with little drug-related 
morbidity. 
MATERIALS AND METHODS 
Of 419 cadaveric renal allograft recipients transplanted at our 
institution between November 1987 and September 1989. 36 
(8.6'T) (25 men and II women) developed invasive CMV infection 
(Table I), Average patient age was 42.1 ± 11.5 years (range. 18 to 
71 years). Infection occurred following the primary transplant in 
28 patients. after the second transplant in Ii- e. and after the third 
Table 1. Clinical Characteristics of 36 Cadaveric Renal 
Transplant Recipients Who Subsequently Developed Invasive 
CMV Disease 
Patient age (y) 
Mean 
Range 
Sex 
Male 
Female 
Panel-reactive antibodies 
<4°'0 
4-80% 
>80% 
Donor age (y) 
Median 
Range 
Donor recipient pretransplant CMV serology 
Positive/negative 
Positive/positive 
Negative/positive 
Negative/negative 
Treated for acute cellular rejection pre-CMV 
Yes 
No 
Type 04 treatment lor acute cellular rejection 
(n = 29) 
High-<Iose steroids 
OKT3 
Steroids and OKT3 
n(%) 
42.1 == 11.5 
18-71 
25 (69) 
11 (31) 
20 (56) 
9 (25) 
7 (19) 
45 
2-67 
16 (44) 
9 (25) 
5 (14) 
4 (11) 
29 (81) 
7 (19) 
18 (SO) 
2 (6) 
9 (25) 
transplant in three. In 16 of the 36 cases (44'7c). an allograft from 
a CMV -seropositi"e (lgG titer> I : 20) donor was transplanted into 
a seronegative recipient. Nine cases (25'7c) were seropositive to 
seropositive. five (14'10 were seronegative to seropositive. and 
four (II '7c) were seronegative to seronegative. Serology .... as not 
available on two grafts. both of which were transplanted into 
seronegative recipients. All patients received a standard immuno-
suppressive regimen consisting of cyclosporine. prednisone. and 
azathioprine, Eighty-one percent of the patients with invasive 
CMV infections had been treated for rejection (prior to developing 
invasive CMV infections) with either increased steroid therapy (n 
= 18. 5O'7c). OKD (n = ~K 6'7c.). or steroids and OKT3 (n = 9 
~R<;EFK An additional eight patients had received prophvlacti~ 
OKT3. Therefore. 19 patients (53'7c) received an average 13.:!-day 
course (range. 6to 19 days) ofOKT3 before contracting CMV. All 
patients had received either "low-dose E~ll mg twice a day. n = 
~UF or "high-dose"lUp to PK~MM mgld based on renal function. n = 
8) prophylactic acyclovir! Thiny-six patients with clinicallv sus-
pected CMV infection (unex.plained fever> 38,3 for >2 day~_ n = 
3 [89'1cJ: leukopenia [white blood cell count <4.000 mL]. n = 21 
[58<;(J: thrombocytopenia «100.000. n = 6 [17'7cJ; diffuse pulmo-
nary infiltrates. n = 9 [25'7cj) were found to have invasive CMV a 
mean of 60.6 days (range_ 28 to 133) after transplantation, Before 
staning ganciclovir. all 36 patients had tissue-invasive CMV 
infection documented by gastric or duodenal mucosal biops~ In = 
~SK 7:!'7c). bronchoalveolar lavage (n = 14. 39'1c). allograft biopsy 
or nephrectomy (n = 6. 11'7c). or liver biopsy (n = I. 3'7c). The 
biopsies were considered positive for CMV based on viral culture 
or histology/immunomicroscopy. Eleven patients OI'7c) had mul-
uple sites involved. At the time of diagnosis. 27 patients (75<;() had 
mild. six. (17'7<) had moderate. and three (8'7<) had severe infection 
according to Peterson et aI's criteria. 10 Ganciclovir (Synte:l.) was 
gi\en at 2.5 mg,kg IV twice a day for a minimum of7 days (mean. 
I ~K:! := 3.5 days) and was continued until the patient was afebrile 
for 5 consecutive days. Dosage was adjusted according to the 
calculated creatinine clearance. 
RESULTS 
Ganciclovir was well tolerated by all 36 patients. Side 
effects were limited to reversible neutropenia (white blood 
cell count <4.<XXl/mL. n = 7). thrombocytopenia 
1< IOO.OOO/mL. n = 2). and rash (n = I). none of which 
required discontinuation of the drug. Serum creatinine 
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(SCr) was unaltered by ganciclovir in those patients with 
functioning grafts (mean SCr, 4.1 ± 1.6 mgldL before and 
3.8 = 1.9 after treatmentl. Clinical improvement occurred 
in all 36 patients following the initial course of treatment. 
Seven patients had persistent asymptomatic viruria and 
(WO had recurrent invasive disease (allograft in one, stom-
ach in one) eradicated with a second course of ganciclovir 
60 and 50 days, respectively, after the first course. There 
was no correlation between CMV severity and recipient 
age (> or <45 years). time to CMV onset after transplant. 
prior rejection, OKT3 use, or use of low-dose versus 
high-dose prophylactic acyclovir (p > .1). Seventeen of 27 
(63'7c) grafts are still functioning (mean follow-up. 12.7 
months) in those patients originally having mild disease, 
three of six grafts (5OCC) in those with moderate disease, 
and zero of three (Oo/c) in those with severe disease (P < 
.02). 
There were 17 graft losses in this series. Four grafts 
",ere already lost at the onset of CMV infection, owing to 
primary graft nonfunction (n = 2) and chronic rejection (n 
= 2). The remaining II grafts were lost from 10 days to 16 
months (median, 5 weeks) following invasive CMV. One 
patient underwent allograft nephrectomy after immuno-
suppression was wit held for transverse myelitis 2 months 
after treatment with ganciclovir. A second patient lost his 
graft to rejection while immunosuppression was wit held 
for acute pancreatitis c with a negative CMV workup) 2 
months after treatment. Another patient had recurrent 
oxalosis and graft failure I year after ganciclovir. The 
remaining grafts were lost to rejection. Of those patients 
that developed CMV without prior rejection. six of seven 
(86'7c) still have functioning allografts, while only I3 of 29 
(45%) are still functioning in patients treated for rejection 
before CMV infection occurred. At mean follow-up of 12.7 
months, the I-year actuarial patient survival is 1009c. The 
I-year actuarial graft survival is 559c :!: UKP~I with a mean 
SCr of 2.5 mgldL (range, 1.2 to 4.6 mgldL). The I-year 
actuarial patient and graft survival rates for the entire 
group of cadaveric rena.! transplants (n = 419) done at our 
institution during the same time period are 94.99c :!: 1.2% 
and 79.7% ± 2.\%. respectively. 
DISCUSSION 
Previous studies have recommended the use of ganciclovir 
only for life- or sight-threatening CMV infection. ~-U In the 
current series, ganciclovir was started as soon as the 
diagnosis of tissue-imasive CMV was made. With this 
approach, 100% patient survival was achieved with only 
1347 
two cases of recurrent CMV infection, both of which 
resp;:nded to a second course of ganciclovir. The graft 
SUf\-;,.al of 55% reponed here is similar to that reported 
pre\).)usly in CMV -infected patients not treated with 
gan:,dovir. 1·.'.10 Eighty-one percent of the patients in our 
se~ experienced at least one rejection episode prior to 
CMY. Thus, this group was at high risk for graft loss even 
had :hey not acquired CMV. In addition. our patients all 
had ~istologically prO\'en disease and might be best cate-
gonz.:d separate from those patients included in other 
stuC:~s in which the diagnosis was largely based on sero-
cor.".ersion and periph~ral cultures. 1·3.10 
a~ring the course of this study, ganciclovir was consid-
ere;: ~xperimental at our institution and was available only 
on i compassionate release basis to patients with biopsy-
prc'·,;;n. invasive CM\' infections. Because the drug ap-
pe"" to be effective \I, ith infrequent sid~ effects. we now 
sta-: ganciclovir if there is a high index of suspicion for 
CMY based on history. physical examination. and serol-
Og!. and continue therapy based on positive cultures 
and 0r tissue biopsy and clinical parameters. We continue 
to ::.se an initial 7-day course of ganciclo\ir and extend the 
trCi:ment for prolonged fever or persistent signs and 
syr:-..ptoms of CMV infection. The limited toxicity and 
prcmpt eradication of symptomatic disease observed in 
thl> series indicate that ganciclovir is a safe and effective 
for:J. of therapy in renal transplant recipients with tissue-
in\bive CMV infection. 
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